Eli Lilly (LLY) Tops $1 Trillion Valuation as Retatrutide Data Fuels Optimism

Eli Lilly (LLY) surged past a $1 trillion market capitalization on May 29, 2026, closing at a record high, as investors priced in the potential of its experimental next-generation obesity drug, retatrutide. The stock has risen more than 25% since the market’s March 30 low, driven by data showing the triple-hormone-targeting therapy could deliver weight loss comparable to bariatric surgery. In the phase 3 TRIUMPH-1 trial, the highest dose of retatrutide led to an average 70.3-pound loss, or 28.3% of body weight, over 80 weeks. Over 45% of patients on that dose shed at least 30% of their body weight. The drug targets three hormone pathways, versus two in Lilly’s approved Zepbound and Mounjaro, signaling a broader metabolic platform that may extend to treat sleep apnea, heart disease, and addiction. The milestone cements Lilly’s role as Wall Street’s primary obesity-drug play, overshadowing rivals Novo Nordisk (NVO), Amgen (AMGN), and Viking Therapeutics (VKTX). The next technical test is the $1,100 level, with a breakout signaling further highs, while a rejection could form a double-top pattern.